No Data
Enhua Pharmaceutical: 2024 Annual Report
Enhua Pharmaceutical: 2024 Annual Report Summary
Jiangsu Nhwa Pharmaceutical (002262.SZ): The net income attributable to the parent company for the 2024 fiscal year is 1.144 billion yuan, with a proposed dividend of 3.6 yuan per share.
Gelonghui, March 28, Jiangsu Nhwa Pharmaceutical (002262.SZ) announced its 2024 annual report, achieving revenue of 5.698 billion yuan in 2024, a year-on-year increase of 13.01%; Net income attributable to shareholders of the listed company was 1.144 billion yuan, a year-on-year increase of 10.28%; Net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.144 billion yuan, a year-on-year increase of 12.88%; Basic EPS was 1.13 yuan; A cash dividend of 3.60 yuan (including tax) is proposed for every 10 shares for all shareholders.
These 4 Measures Indicate That Jiangsu Nhwa Pharmaceutical (SZSE:002262) Is Using Debt Safely
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Nhwa Pharmaceutical to Buy Stake in NeuroThree Therapeutics for $3.5 Million
Little Excitement Around Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Earnings
